Project Grant R21HL175588
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $234K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $754,729 to the University of Pittsburgh to investigate the mechanisms by which respiratory viral infections, including COVID-19, can lead to persistent lung inflammation and damage. The research aims to understand how viral antigen persistence in pulmonary endothelial cells drives chronic activation of CD8+ T cells, leading to long-term pulmonary sequelae. The...
- This $131,988 Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, supports research targeting determinants of SARS-CoV-2 host interaction in airways. Funded through the Cardiovascular Diseases Research program, the grant aims to identify master regulator proteins that mechanistically regulate SARS-CoV-2 interactions in the airways. Using organotypic airway epithelial culture and systems biology tools at Columbia University, the...
- This federal Project Grant award of $411,400 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a synthetic miRNA-7702 as a potential therapeutic approach for treating SARS-CoV-2 infection. The project aims to elucidate the mechanism by which miRNA-7702 inhibits SARS-CoV-2 replication and to evaluate the in vivo efficacy and safety of the synthetic miRNA-7702 in a preclinical mouse model. The grant...
- The National Heart, Lung, and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $391,250.00 Project Grant to Emory University to investigate the role of fibrinogen as a mediator of COVID-19-associated coagulopathy. The award, effective from March 1, 2025 to February 29, 2028, will support a series of experiments testing the hypothesis that elevated fibrinogen levels contribute to the severe coagulation issues observed in critical...
- This Project Grant award in the amount of $167,940 was provided by the National Heart Lung and Blood Institute (CFDA# 93.837 Cardiovascular Diseases Research) to the Icahn School of Medicine at Mount Sinai to support research investigating the impact of pulmonary influenza infection on the pathogenesis of myocardial infarction and heart failure. The project aims to comprehensively probe the hypothesis that influenza A virus translocates from the lung to the heart, inducing an antiviral...
- The National Heart Lung and Blood Institute awarded a $503,637 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. This grant, awarded on January 15, 2025, supports research to investigate the mechanisms of thrombosis (blood clots) in patients with COVID-19 infection. The key objectives are to measure changes in the hemostatic (clotting) and fibrinolytic (clot-dissolving) systems in COVID-19 patients from initial...
- This federal Project Grant award of $2,981,544.00, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a study to assess the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with treated HIV infection. The study will leverage data from a prior clinical trial of the CMV-specific antiviral drug letermovir and a case-cohort study of over 1,900 ART-suppressed people with HIV to...
- This $292,500 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to identify novel microproteins associated with normal hematopoiesis and hematopoietic diseases. The project will leverage existing transcriptomic and translation data to produce a comprehensive catalog of microproteins expressed in different hematopoietic cell types. This inter-disciplinary research conducted by the Sanford Burnham Prebys Medical Discovery...
- The federal Project Grant award of $678,803.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to The Ohio State University. The funding supports research to investigate the role of the mitochondrial deubiquitinase USP30 in regulating microvascular endothelial cell function and its potential as a therapeutic target for acute inflammatory diseases like acute respiratory distress syndrome (ARDS) and sepsis. Key...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $639,740.00 to investigate the role of the CD38 enzyme in the development of chronic lung conditions following viral infections like COVID-19. The research aims to explore how targeting CD38 on CD8 tissue resident memory (TRM) cells could mitigate age-associated lung fibrosis after viral pneumonia. The award, effective December 15, 2024 through November 30, 2029, will support the lead researcher...